To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
Here is a small sampling of Sturge-Weber Syndrome and Related Diseases studies by title:
Ready to become a subscriber? Go to our PRICING page.
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
Here is a small sampling of Sturge-Weber Syndrome and Related Diseases studies by title:
Ready to become a subscriber? Go to our PRICING page.
Sturge-Weber Syndrome (SWS) is a rare neurological disorder that typically manifests at birth and is characterized by a combination of vascular malformations, including a distinctive port-wine stain (a red or purple birthmark) on the face. This condition is caused by a mutation in the GNAQ gene, leading to abnormal blood vessel development in certain areas of the body, particularly in the skin and brain. The port-wine stain usually appears on one side of the face, often following the distribution of the trigeminal nerve, and is one of the most recognizable features of the syndrome.
Along with the visible birthmark, individuals with SWS often experience a range of neurological symptoms. Seizures are common, usually beginning in early childhood, and can vary from focal to generalized seizures. Over time, these seizures can become difficult to control, which may contribute to developmental delays and intellectual disabilities in some individuals. Additionally, hemiparesis, or weakness on one side of the body, is another potential symptom resulting from brain malformations caused by abnormal blood vessel formation. These malformations can also lead to stroke-like episodes, causing sudden neurological deficits such as weakness, difficulty speaking, or loss of coordination.
Eye-related issues are also prevalent in SWS, particularly glaucoma. The abnormal blood vessels in the eye can increase intraocular pressure, leading to this condition, which can ultimately result in vision loss if not properly managed. Alongside glaucoma, individuals may also face other visual impairments.
While the symptoms of SWS can vary, some individuals may experience cognitive impairments or learning difficulties, making special education and therapy a critical part of their care. Chronic headaches are also common, often stemming from pressure within the brain or eyes.
Diagnosing SWS typically involves recognizing the characteristic port-wine stain and confirming the condition with imaging studies, such as MRI or CT scans, which reveal brain malformations. Genetic testing can also identify the mutation in the GNAQ gene.
Managing the disorder is multifaceted, with treatment focusing on controlling symptoms. Seizure medications are commonly prescribed to reduce the frequency and intensity of seizures, while glaucoma treatments help manage intraocular pressure. Support for developmental challenges is essential, often through special education programs and therapy. In some cases, surgical interventions may be required to treat complications in the brain or eyes.
Though SWS is a lifelong condition, many individuals can lead fulfilling lives with proper care and ongoing support. A multidisciplinary healthcare team, including neurologists, ophthalmologists, and developmental specialists, is often essential in managing the various aspects of the disorder.
For more information on SWS click here (K. Achint et al., 2023)
If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.
If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).
However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.